Michele Libonati

8 papers receiving 1.2k citations

Michele Libonati's Hit Papers

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis 2003 · 1.0k citations
1.0k0+7+15Years since publication2505007501000

Peers

Michele Libonati
Comparison fields: 5 of 73
  • Pathology and Forensic Medicine 618
  • Immunology and Allergy 153
  • Immunology 425
  • Oncology 368
  • Neurology 189
Replace Laura R. Tranquill with:
Laura R. Tranquill United States
Cheryl M. Bergman United States
Naoyuki Tsukada Japan
Thomas Prod’homme United States
Ryan C. Winger United States
Robert Medaer Belgium
Martin Toal United Kingdom
Iris Ferber Germany
Christine Ewing Australia
Hartmut Wekerle Germany
Michele Libonati relative to Laura R. Tranquill United States Laura R. Tranquill's profile →
Citations per field
00.5×2×2.8×
Laura R. Tranquill · 1×
Citations per year

Countries citing papers authored by Michele Libonati

Since Specialization
Citations

This map shows the geographic impact of Michele Libonati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Libonati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Libonati more than expected).

Fields of papers citing papers by Michele Libonati

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Libonati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Libonati. The network helps show where Michele Libonati may publish in the future.

Co-authors

The 25 scholars most cited alongside Michele Libonati, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michele Libonati Line = papers co-authored together Michele Libonati links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Hit paper breakdown →
20031045
2 2004126
3 200753
4 199746
5 200436
6 199210
7 20057
8
[Research on cephalotoxin. 2. On some pharmacological properties of the substance].
19591

About Michele Libonati

Michele Libonati is a scholar working on Pathology and Forensic Medicine, Cellular and Molecular Neuroscience, Pharmaceutical Science, Genetics and Hematology, having authored 8 papers that have together received 1.3k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (3 papers), Inflammatory Bowel Disease (2 papers), Autoimmune and Inflammatory Disorders Research (1 paper), Pluripotent Stem Cells Research (1 paper), Immunodeficiency and Autoimmune Disorders (1 paper), Chemical Reactions and Isotopes (1 paper), Neurological disorders and treatments (1 paper) and Neurotransmitter Receptor Influence on Behavior (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (618 citations), Immunology and Allergy (153 citations), Immunology (425 citations), Oncology (368 citations) and Neurology (189 citations). Michele Libonati has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include William A. Sheremata, George P. Rice, Catherine M. Dalton, Paul W O'Connor, David H. Miller, Lance D. Blumhardt, Omar Khan, Katherine Miszkiel, Andrew D. Goodman and L Metz. Their work appears in journals such as Journal of Pediatric Gastroenterology and Nutrition, New England Journal of Medicine, Experimental Neurology, Neurology and Multiple Sclerosis Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact